Models to predict prevalence and transition dynamics of methicillin-resistant Staphylococcus aureus in community nursing homes

American Journal of Infection Control
Nataliya G BatinaDörte Döpfer

Abstract

Recent spread of USA300 methicillin-resistant Staphylococcus aureus (MRSA) to nursing homes has been of particular concern. We sought to predict the ultimate prevalence of USA300 and non-USA300 MRSA and to examine the influence of potential risk factors on MRSA acquisition in community nursing homes. The data were collected during a longitudinal MRSA surveillance study that involved 449 residents in 6 community nursing homes in Wisconsin. The subjects were screened every 3 months for up to 1 year. Markov chain models were employed to predict strain-specific prevalence of MRSA at steady state, and to assess the influence of potential risk factors, including recent hospitalizations, invasive medical devices, and antibiotic exposure on MRSA acquisition rates and average duration of colonization. At steady state, 20% (95% confidence interval [CI], 15%-25%) of residents were predicted to remain colonized with non-USA300 and 4% (95% CI, 2%-7%) with USA300 MRSA. Residents who used antibiotics during the previous 3 months were twice more likely to acquire MRSA than those who did not (acquisition rates, 0.052; 95% CI, 0.038-0.075 and 0.025; 95% CI, 0.018-0.037, respectively). Non-USA300 was predicted to remain the dominant MRSA strain i...Continue Reading

References

Oct 1, 1986·Journal of the American Geriatrics Society·J G ZimmerN M Watson
Jul 1, 1994·Journal of Gerontology·J N MorrisL A Lipsitz
Feb 18, 1999·JAMA : the Journal of the American Medical Association·J WienerR A Weinstein
Sep 1, 2000·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·L E NicolleP W Smith
Jan 22, 2003·Journal of the American Geriatrics Society·Blair CapitanoDavid P Nicolau
Sep 21, 1963·JAMA : the Journal of the American Medical Association·S KATZM W JAFFE
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Timothy S NaimiRuth Lynfield
Jun 29, 2004·Proceedings of the National Academy of Sciences of the United States of America·B S CooperS Ebrahim
Mar 11, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Sara E CosgroveYehuda Carmeli
Mar 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·M C J BootsmaM J M Bonten
Dec 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy H DellitUNKNOWN Society for Healthcare Epidemiology of America
Oct 18, 2007·JAMA : the Journal of the American Medical Association·R Monina KlevensUNKNOWN Active Bacterial Core surveillance (ABCs) MRSA Investigators
Apr 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lona ModySuzanne F Bradley
Jun 16, 2009·Emerging Infectious Diseases·Pierre TattevinFrançoise Perdreau-Remington
Jun 30, 2009·Journal of the American Medical Directors Association·Michele GaraziGisele Wolf-Klein
Jul 18, 2009·The Journal of Antimicrobial Chemotherapy·Fred C Tenover, Richard V Goering
Oct 21, 2009·Proceedings of the National Academy of Sciences of the United States of America·Laura TemimeDidier Guillemot
Nov 23, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Courtney ReynoldsSusan S Huang
Apr 5, 2011·American Journal of Infection Control·Rishi DesaiLoren G Miller
Apr 5, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Maia LesoskyJanet Raboud
Apr 5, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jon P FurunoMary-Claire Roghmann
Aug 26, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sarah Y WonUNKNOWN Centers for Disease Control and Prevention Epicenter Program
Oct 21, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Sean L BarnesJon P Furuno
May 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Nimalie D StoneUNKNOWN Southeast Veterans Affairs Long-Term Care Methicillin-Resistant Staphylococcus aureus Cooperative
Oct 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Christopher J CrnichPaul Drinka
Feb 8, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Courtney R MurphySusan S Huang
Sep 18, 2013·JAMA Internal Medicine·Raymund DantesUNKNOWN Emerging Infections Program–Active Bacterial Core Surveillance MRSA Surveillance Investigators

❮ Previous
Next ❯

Citations

Oct 1, 2016·Antimicrobial Resistance and Infection Control·Nataliya G BatinaDörte Döpfer
Jun 23, 2020·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Ahmed AlbarragAmani Al-Amodi
May 8, 2018·Annals of Clinical Microbiology and Antimicrobials·Monica da SilveiraCarlos Magno Castelo Branco Fortaleza

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Eduardo A F FreitasCassandra D Salgado
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
S M ShurlandMary-Claire Roghmann
Journal of the American Medical Directors Association
Michele GaraziGisele Wolf-Klein
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
B WarshawskyL Schiedel
© 2022 Meta ULC. All rights reserved